Bevacizumab news

Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16

KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.

FDA approves KEYTRUDA regimens for platinum-resistant ovarian cancer, showing reduced disease progression and death risk in trials.

FDA grants Breakthrough Therapy status to sofetabart mipitecan for platinum-resistant ovarian cancer, based on promising Phase 1 results. Phase 3 trial underway.

Raludotatug deruxtecan achieved a 50.5% response rate in phase 2 for platinum-resistant ovarian cancer, with a 5.6 mg/kg dose selected for phase 3.